Abstinence-contingent incentives improved smoking cessation outcomes among economically disadvantaged smokers with mental illness.
Abstinent smokers may have reduced preoperative pain tolerance and increased postoperative opioid use compared with nonsmokers.
Using data from the TUS-CPS, researchers sought to determine the effect of pharmaceutical smoking cessation aids on long-term quit rates among patients who smoke tobacco.
SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.
Nab-paclitaxel/carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on ChemotherapyDecember 01, 2017
[Lung Cancer: Targets and Therapy] Researchers examine the affect of first-line nab-paclitaxel plus carboplatinon QoL for patients with advanced non-small cell lung cancer.
Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.
In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.
Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.
Populating a microsimulation of model of HIV disease, researchers investigated the the likelihood of lung cancer-related morbidity and mortality among patients with HIV who smoke, based on smoking intensity.
A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.
This study evaluated the feasibility and potential efficacy of a yoga intervention for patients with NSCLC and their caregivers.
Impact of language barrier and patient ethnicity on time interval from diagnosis to treatment for patients with NSCLC was measured at a public hospital and a private hospital.
In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.
PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.
Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in TherapyOctober 13, 2017
[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.
Combining radiotherapy and immunotherapy has shown early promise against some advanced cancers, but oncology nurses need to be wary of potential overlapping toxicity profiles from each of these treatment modalities.
Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.
This case demonstrates that, although rare, spontaneous TLS can occur even in the absence of chemotherapy, and a high index of suspicion for the effect should be maintained when patients with malignancies demonstrate the classic symptom of laboratory abnormalities.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.
Significant increases seen in heart rate and arterial stiffness were observed in the first 30 minutes after smoking electronic-cigarette containing nicotine.
Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.
An investigation into the challenges of lung cancer clinical trials found that despite a lack of participants being detrimental to successful trial completion, clinical trials are trending toward increasing their eligibility criteria, making it more difficult to accrue enough eligible participants.
Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challengesSeptember 01, 2017
[Lung Cancer: Targets and Therapy] Chronic obstructive pulmonary disease and lung cancer share a common etiological factor and usually coexist in everyday clinical practice.
Vitamin B intake appears to be related to lung cancer risk, but only for men or male smokers.
A retrospective analysis showed an association between depth of response (DepOR) and greater overall survival and longer progression-free survival.
[Lung Cancer: Targets and Therapy] This research reviews the current literature on psychosocial interventions in lung cancer, and discusses .
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|